CAS 432001-19-9 – N-[4-hydroxy-3-(2-hydroxynaphtha… | In Stock

CAS No.

432001-19-9

MDL No.

MFCD03141581

C₂₇H₂₁NO₅S

471.50

InChI Key

QDCJDYWGYVPBDO-UHFFFAOYSA-N

Pack Size	Purity	Price	Availability
25 mg	96%	$124	In Stock
50 mg	96%	$183	In Stock
100 mg	96%	$310	In Stock
250 mg	96%	$525	In Stock
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

25 mg

96%

$124

In Stock

50 mg

96%

$183

In Stock

100 mg

96%

$310

In Stock

250 mg

96%

$525

In Stock

Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	432001-19-9
Product Name	N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide

Associated Conditions

head and neck squamous cell carcinoma·breast cancer·idiopathic pulmonary fibrosis·hepatocellular carcinoma·pancreatic carcinoma

* The information provided here is compiled from public sources and is for reference only.

N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Documentation

N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

Hepatocytic AP-1 and STAT3 contribute to chemotaxis in alphanaphthylisothiocyanate-induced cholestatic liver injury.

Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors.

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.

Documentation